Presentation SIF 2019 Top 4 Structural Trials of the Last Year Presenter: Michael J Reardon March 27, 2019
Presentation ACC 2019 PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis Presenter: Martin B. Leon March 17, 2019
Presentation TCT 2018 PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve Presenter: John G. Webb September 23, 2018
Presentation TCT 2018 Neurology-Cardiology Partnership Presenter: Robert J. Sommer, Christian Spies, Suzanne J. Baron, Reda Ibrahim, Carey D. Kimmelstiel, Srihari S. Naidu, Zoltan G. Turi, Dominik M. Wiktor September 22, 2018
Presentation TCT 2018 TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER Presenter: Charles J. Davidson, Jeffrey J. Popma, Matthew Summers September 21, 2018
Presentation CHIP Seattle 2018 How to Manage Your Attending/Partners as You Take on CHIP Cases Presenter: Robert F. Riley August 10, 2018
Presentation The Structural Heart Disease Summit 2018 Partner 3 Low-Risk Presenter: Martin B. Leon June 21, 2018
Presentation The Structural Heart Disease Summit 2018 Updates from the PARTNER Aortic Valve-in-Valve Registry Presenter: Vinayak Bapat, Ran Kornowski, Michael J. Mack June 21, 2018
Presentation The Structural Heart Disease Summit 2018 Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded June 21, 2018
Presentation EuroPCR 2018 Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies Presenter: E. Murat Tuzcu May 25, 2018
Presentation TCT 2017 Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER Presenter: Pamela S. Douglas November 01, 2017
Presentation TCT 2017 TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD November 01, 2017
Presentation TCT 2017 TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials Presenter: Peter C. Block, Lars Sondergaard, Tarun Chakravarty, MD October 31, 2017
Presentation TCT 2017 PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis Presenter: Patrick W. Serruys, David J. Cohen October 31, 2017
Presentation TCT 2017 Important Clinical Lessons From the VIVID Registry and the PARTNER Experience Presenter: John G. Webb October 30, 2017
Presentation TCT 2017 Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients Presenter: Michael J. Reardon October 30, 2017
Presentation TCT 2017 Take-home Messages and Closing Comments Presenter: Amal Kumar Banerjee, Rabin dra Nath Chakraborty October 29, 2017
Presentation TCT 2017 Clinical Case #4: A Complex and High-Risk PCI Presenter: Anibal A. Damonte, Alejandro O. Palacios, Alejandro Cherro October 29, 2017